<DOC>
	<DOCNO>NCT00127829</DOCNO>
	<brief_summary>This study determine safety profile maximum tolerate dose ( MTD ) orally administer gefitinib weekly twice weekly schedule .</brief_summary>
	<brief_title>Study Evaluating Gefitinib ( IRESSAÂ® ) Subjects With Solid Malignancies That Are Locally Advanced , Recurrent Metastatic</brief_title>
	<detailed_description />
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically confirm solid tumor refractory conventional treatment standard treatment exist Life expectancy &gt; 12 week World Health Organization ( WHO ) performance status &lt; 2 Known severe hypersensitivity gefitinib excipients product Less 4 week since completion prior chemotherapy radiation therapy ( except nitrosoureas mitomycinC must wash period 6 week ) Incomplete heal previous oncologic major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Solid Tumors</keyword>
</DOC>